Picture
SEARCH
What are you looking for?
Need help finding what you are looking for? Contact Us
Compare
Free Samples
Pipeline Analysis

PUBLISHER: Global Industry Analysts, Inc. | PRODUCT CODE: 1794524

Cover Image

PUBLISHER: Global Industry Analysts, Inc. | PRODUCT CODE: 1794524

Nontuberculous Mycobacterial Infections

PUBLISHED:
PAGES: 279 Pages
DELIVERY TIME: 1-2 business days
REQUEST FREE SAMPLE
REQUEST CUSTOMIZATION
SELECT AN OPTION
PDF (Single User License)
USD 5850
PDF (Global License to Company and its Fully-owned Subsidiaries)
USD 17550

Add to Cart

Description

Table of Contents

Global Nontuberculous Mycobacterial Infections Market to Reach US$18.3 Billion by 2030

The global market for Nontuberculous Mycobacterial Infections estimated at US$14.0 Billion in the year 2024, is expected to reach US$18.3 Billion by 2030, growing at a CAGR of 4.5% over the analysis period 2024-2030. Clarithromycin, one of the segments analyzed in the report, is expected to record a 5.6% CAGR and reach US$7.1 Billion by the end of the analysis period. Growth in the Azithromycin segment is estimated at 2.9% CAGR over the analysis period.

The U.S. Market is Estimated at US$3.8 Billion While China is Forecast to Grow at 8.4% CAGR

The Nontuberculous Mycobacterial Infections market in the U.S. is estimated at US$3.8 Billion in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$3.8 Billion by the year 2030 trailing a CAGR of 8.4% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 1.8% and 3.6% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 2.7% CAGR.

Global Nontuberculous Mycobacterial Infections Market - Key Trends & Drivers Summarized

Why Are Nontuberculous Mycobacteria (NTM) Gaining Clinical Attention?

Infections caused by nontuberculous mycobacteria have become a growing concern due to increasing identification in patients with chronic lung conditions, such as bronchiectasis, COPD, or cystic fibrosis. These environmental bacteria are found in soil, water systems, and biofilms and can cause persistent, difficult-to-treat pulmonary infections. Increased awareness among pulmonologists, coupled with more frequent use of high-resolution imaging and sputum cultures, has led to a rise in confirmed diagnoses globally.

NTM infections can also occur in skin and soft tissue, lymph nodes, and disseminated in immunocompromised individuals. Clinical recognition has improved through updated guidelines that encourage suspicion in patients with unexplained respiratory symptoms and persistent nodular or bronchiectatic changes on CT scans. This heightened vigilance has driven more systematic screening and laboratory testing, making infection rates appear to rise even as actual incidence increases.

How Are Diagnostic and Treatment Innovations Improving Patient Outcomes?

Diagnostic methods for NTM are evolving beyond traditional culture-based techniques. Molecular assays, such as PCR and line probe assays, enable faster species identification and antimicrobial resistance detection. This precision allows clinicians to tailor antibiotic regimens early in therapy, improving treatment success. Research into novel biomarkers and advanced imaging techniques is helping differentiate active infection from colonization, addressing a key challenge in clinical management.

Therapeutic approaches now combine multiple antimycobacterial agents administered for long durations, often exceeding 12 months. Newer drugs-such as inhaled amikacin liposome suspension and oxazolidinones-offer targeted therapy with reduced systemic toxicity. Adjunct treatments, including airway clearance devices and pulmonary rehabilitation, support lung function and treatment adherence. Clinical trials are testing immunomodulatory agents to boost host response and reduce bacterial burden, with promising early-stage results.

What Care Models and Management Strategies Are Emerging?

Management of NTM infections increasingly relies on multidisciplinary care teams that include pulmonologists, infectious disease specialists, radiologists, and pharmacists. Comprehensive care hubs offer coordinated diagnostics, treatment initiation, monitoring of drug interactions, side effects, and adherence support. Telehealth tools and digital reminders are also being used to monitor long-term treatment compliance and track adverse effects remotely.

Patient education and support groups are gaining importance in treatment frameworks. Sustained patient engagement through digital platforms helps manage the emotional and logistical challenges of prolonged therapy. Health systems are beginning to develop NTM-specific registries that collect data on treatment outcomes, species distribution, and regional epidemiology, enabling more informed decision-making and benchmarking.

Growth in the nontuberculous mycobacterial infections market is driven by several factors.

Increasing prevalence of NTM infections, especially among aging and immunocompromised populations, is expanding patient pools and clinical awareness. Advances in molecular diagnostics are enabling faster and more accurate species identification and resistance profiling. Introduction of novel antimycobacterial drugs and inhaled delivery systems is offering alternatives to standard therapies. Emergence of multidisciplinary care models supported by telehealth and digital adherence tools is improving long-term treatment success. Finally, formation of patient registries and growing research into NTM epidemiology and therapeutics are fostering treatment innovation and adoption of best practices by healthcare providers.

SCOPE OF STUDY:

The report analyzes the Nontuberculous Mycobacterial Infections market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Drug Type (Clarithromycin, Azithromycin, Rifampin, Rifabutin, Other Drug Types); Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 36 Featured) -

  • Abbott Laboratories
  • Astellas Pharma Inc.
  • AstraZeneca PLC
  • Bayer AG
  • BioMarin Pharmaceutical Inc.
  • Bristol Myers Squibb
  • Cipla Ltd.
  • Eli Lilly and Company
  • F. Hoffmann-La Roche AG
  • GlaxoSmithKline PLC
  • Insmed Incorporated
  • Janssen (Johnson & Johnson)
  • MannKind Corporation
  • Merck & Co. Inc.
  • Novartis AG
  • Paratek Pharmaceuticals Inc.
  • Pfizer Inc.
  • RedHill Biopharma Ltd.
  • Sanofi S.A.
  • Spero Therapeutics Inc.
  • Sun Pharmaceutical Industries Ltd.
  • Teva Pharmaceutical Industries Ltd.
  • Vertex Pharmaceuticals Inc.
  • Zydus Lifesciences Ltd.

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

Show more
Product Code: MCP37514

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • World Market Trajectories
    • Tariff Impact on Global Supply Chain Patterns
    • Nontuberculous Mycobacterial Infections - Global Key Competitors Percentage Market Share in 2025 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Rising Incidence of Nontuberculous Mycobacterial (NTM) Infections Drives Demand for Targeted Diagnostics and Therapies
    • Increased Awareness and Improved Diagnostic Capabilities Lead to Higher Detection Rates of NTM Lung Disease
    • Expansion of At-Risk Populations, Including the Elderly and Immunocompromised, Fuels Market Demand
    • Advancements in Molecular and Culture-Based Diagnostic Tools Enhance Early Identification and Species Differentiation
    • Growing Prevalence of Underlying Pulmonary Conditions Like COPD and Bronchiectasis Spurs NTM Management Needs
    • Surge in Macrolide-Resistant Strains Throws the Spotlight on Development of New Antimicrobial Regimens
    • Rising Clinical Attention Toward Non-Responsive TB Cases Supports Greater NTM Testing and Surveillance
    • Emerging Role of Biofilm Research and Intracellular Pathogen Studies Improves Therapeutic Targeting
    • Regulatory Push for Drug Development in Rare and Refractory Infections Encourages Investment in NTM Therapies
    • Increasing Use of Combination Antibiotic Therapies Promotes Long-Term Treatment Management Strategies
    • Globalization of Airborne Infectious Risk Awareness Promotes Proactive Screening and Treatment Guidelines
    • Integration of Next-Generation Sequencing and Genomic Typing Enhances Pathogen Surveillance and Resistance Mapping
    • Rise in Hospital-Acquired and Post-Surgical Infections Linked to NTM Underscores Need for Enhanced Prevention
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Nontuberculous Mycobacterial Infections Market Analysis of Annual Sales in US$ Million for Years 2014 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Nontuberculous Mycobacterial Infections by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 3: World Historic Review for Nontuberculous Mycobacterial Infections by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 4: World 16-Year Perspective for Nontuberculous Mycobacterial Infections by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2014, 2025 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Clarithromycin by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 6: World Historic Review for Clarithromycin by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 7: World 16-Year Perspective for Clarithromycin by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Azithromycin by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 9: World Historic Review for Azithromycin by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 10: World 16-Year Perspective for Azithromycin by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Rifampin by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 12: World Historic Review for Rifampin by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 13: World 16-Year Perspective for Rifampin by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Rifabutin by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 15: World Historic Review for Rifabutin by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 16: World 16-Year Perspective for Rifabutin by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 17: World Recent Past, Current & Future Analysis for Other Drug Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 18: World Historic Review for Other Drug Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 19: World 16-Year Perspective for Other Drug Types by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 20: World Recent Past, Current & Future Analysis for Hospital Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 21: World Historic Review for Hospital Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 22: World 16-Year Perspective for Hospital Pharmacies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 23: World Recent Past, Current & Future Analysis for Retail Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 24: World Historic Review for Retail Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 25: World 16-Year Perspective for Retail Pharmacies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 26: World Recent Past, Current & Future Analysis for Online Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 27: World Historic Review for Online Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 28: World 16-Year Perspective for Online Pharmacies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Nontuberculous Mycobacterial Infections Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 29: USA Recent Past, Current & Future Analysis for Nontuberculous Mycobacterial Infections by Drug Type - Clarithromycin, Azithromycin, Rifampin, Rifabutin and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 30: USA Historic Review for Nontuberculous Mycobacterial Infections by Drug Type - Clarithromycin, Azithromycin, Rifampin, Rifabutin and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 31: USA 16-Year Perspective for Nontuberculous Mycobacterial Infections by Drug Type - Percentage Breakdown of Value Sales for Clarithromycin, Azithromycin, Rifampin, Rifabutin and Other Drug Types for the Years 2014, 2025 & 2030
    • TABLE 32: USA Recent Past, Current & Future Analysis for Nontuberculous Mycobacterial Infections by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 33: USA Historic Review for Nontuberculous Mycobacterial Infections by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 34: USA 16-Year Perspective for Nontuberculous Mycobacterial Infections by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2014, 2025 & 2030
  • CANADA
    • TABLE 35: Canada Recent Past, Current & Future Analysis for Nontuberculous Mycobacterial Infections by Drug Type - Clarithromycin, Azithromycin, Rifampin, Rifabutin and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 36: Canada Historic Review for Nontuberculous Mycobacterial Infections by Drug Type - Clarithromycin, Azithromycin, Rifampin, Rifabutin and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 37: Canada 16-Year Perspective for Nontuberculous Mycobacterial Infections by Drug Type - Percentage Breakdown of Value Sales for Clarithromycin, Azithromycin, Rifampin, Rifabutin and Other Drug Types for the Years 2014, 2025 & 2030
    • TABLE 38: Canada Recent Past, Current & Future Analysis for Nontuberculous Mycobacterial Infections by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 39: Canada Historic Review for Nontuberculous Mycobacterial Infections by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 40: Canada 16-Year Perspective for Nontuberculous Mycobacterial Infections by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2014, 2025 & 2030
  • JAPAN
    • Nontuberculous Mycobacterial Infections Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 41: Japan Recent Past, Current & Future Analysis for Nontuberculous Mycobacterial Infections by Drug Type - Clarithromycin, Azithromycin, Rifampin, Rifabutin and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 42: Japan Historic Review for Nontuberculous Mycobacterial Infections by Drug Type - Clarithromycin, Azithromycin, Rifampin, Rifabutin and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 43: Japan 16-Year Perspective for Nontuberculous Mycobacterial Infections by Drug Type - Percentage Breakdown of Value Sales for Clarithromycin, Azithromycin, Rifampin, Rifabutin and Other Drug Types for the Years 2014, 2025 & 2030
    • TABLE 44: Japan Recent Past, Current & Future Analysis for Nontuberculous Mycobacterial Infections by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 45: Japan Historic Review for Nontuberculous Mycobacterial Infections by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 46: Japan 16-Year Perspective for Nontuberculous Mycobacterial Infections by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2014, 2025 & 2030
  • CHINA
    • Nontuberculous Mycobacterial Infections Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 47: China Recent Past, Current & Future Analysis for Nontuberculous Mycobacterial Infections by Drug Type - Clarithromycin, Azithromycin, Rifampin, Rifabutin and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 48: China Historic Review for Nontuberculous Mycobacterial Infections by Drug Type - Clarithromycin, Azithromycin, Rifampin, Rifabutin and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 49: China 16-Year Perspective for Nontuberculous Mycobacterial Infections by Drug Type - Percentage Breakdown of Value Sales for Clarithromycin, Azithromycin, Rifampin, Rifabutin and Other Drug Types for the Years 2014, 2025 & 2030
    • TABLE 50: China Recent Past, Current & Future Analysis for Nontuberculous Mycobacterial Infections by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 51: China Historic Review for Nontuberculous Mycobacterial Infections by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 52: China 16-Year Perspective for Nontuberculous Mycobacterial Infections by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2014, 2025 & 2030
  • EUROPE
    • Nontuberculous Mycobacterial Infections Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 53: Europe Recent Past, Current & Future Analysis for Nontuberculous Mycobacterial Infections by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 54: Europe Historic Review for Nontuberculous Mycobacterial Infections by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 55: Europe 16-Year Perspective for Nontuberculous Mycobacterial Infections by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2014, 2025 & 2030
    • TABLE 56: Europe Recent Past, Current & Future Analysis for Nontuberculous Mycobacterial Infections by Drug Type - Clarithromycin, Azithromycin, Rifampin, Rifabutin and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 57: Europe Historic Review for Nontuberculous Mycobacterial Infections by Drug Type - Clarithromycin, Azithromycin, Rifampin, Rifabutin and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 58: Europe 16-Year Perspective for Nontuberculous Mycobacterial Infections by Drug Type - Percentage Breakdown of Value Sales for Clarithromycin, Azithromycin, Rifampin, Rifabutin and Other Drug Types for the Years 2014, 2025 & 2030
    • TABLE 59: Europe Recent Past, Current & Future Analysis for Nontuberculous Mycobacterial Infections by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 60: Europe Historic Review for Nontuberculous Mycobacterial Infections by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 61: Europe 16-Year Perspective for Nontuberculous Mycobacterial Infections by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2014, 2025 & 2030
  • FRANCE
    • Nontuberculous Mycobacterial Infections Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 62: France Recent Past, Current & Future Analysis for Nontuberculous Mycobacterial Infections by Drug Type - Clarithromycin, Azithromycin, Rifampin, Rifabutin and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 63: France Historic Review for Nontuberculous Mycobacterial Infections by Drug Type - Clarithromycin, Azithromycin, Rifampin, Rifabutin and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 64: France 16-Year Perspective for Nontuberculous Mycobacterial Infections by Drug Type - Percentage Breakdown of Value Sales for Clarithromycin, Azithromycin, Rifampin, Rifabutin and Other Drug Types for the Years 2014, 2025 & 2030
    • TABLE 65: France Recent Past, Current & Future Analysis for Nontuberculous Mycobacterial Infections by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 66: France Historic Review for Nontuberculous Mycobacterial Infections by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 67: France 16-Year Perspective for Nontuberculous Mycobacterial Infections by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2014, 2025 & 2030
  • GERMANY
    • Nontuberculous Mycobacterial Infections Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 68: Germany Recent Past, Current & Future Analysis for Nontuberculous Mycobacterial Infections by Drug Type - Clarithromycin, Azithromycin, Rifampin, Rifabutin and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 69: Germany Historic Review for Nontuberculous Mycobacterial Infections by Drug Type - Clarithromycin, Azithromycin, Rifampin, Rifabutin and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 70: Germany 16-Year Perspective for Nontuberculous Mycobacterial Infections by Drug Type - Percentage Breakdown of Value Sales for Clarithromycin, Azithromycin, Rifampin, Rifabutin and Other Drug Types for the Years 2014, 2025 & 2030
    • TABLE 71: Germany Recent Past, Current & Future Analysis for Nontuberculous Mycobacterial Infections by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 72: Germany Historic Review for Nontuberculous Mycobacterial Infections by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 73: Germany 16-Year Perspective for Nontuberculous Mycobacterial Infections by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2014, 2025 & 2030
  • ITALY
    • TABLE 74: Italy Recent Past, Current & Future Analysis for Nontuberculous Mycobacterial Infections by Drug Type - Clarithromycin, Azithromycin, Rifampin, Rifabutin and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 75: Italy Historic Review for Nontuberculous Mycobacterial Infections by Drug Type - Clarithromycin, Azithromycin, Rifampin, Rifabutin and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 76: Italy 16-Year Perspective for Nontuberculous Mycobacterial Infections by Drug Type - Percentage Breakdown of Value Sales for Clarithromycin, Azithromycin, Rifampin, Rifabutin and Other Drug Types for the Years 2014, 2025 & 2030
    • TABLE 77: Italy Recent Past, Current & Future Analysis for Nontuberculous Mycobacterial Infections by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 78: Italy Historic Review for Nontuberculous Mycobacterial Infections by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 79: Italy 16-Year Perspective for Nontuberculous Mycobacterial Infections by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2014, 2025 & 2030
  • UNITED KINGDOM
    • Nontuberculous Mycobacterial Infections Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 80: UK Recent Past, Current & Future Analysis for Nontuberculous Mycobacterial Infections by Drug Type - Clarithromycin, Azithromycin, Rifampin, Rifabutin and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 81: UK Historic Review for Nontuberculous Mycobacterial Infections by Drug Type - Clarithromycin, Azithromycin, Rifampin, Rifabutin and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 82: UK 16-Year Perspective for Nontuberculous Mycobacterial Infections by Drug Type - Percentage Breakdown of Value Sales for Clarithromycin, Azithromycin, Rifampin, Rifabutin and Other Drug Types for the Years 2014, 2025 & 2030
    • TABLE 83: UK Recent Past, Current & Future Analysis for Nontuberculous Mycobacterial Infections by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 84: UK Historic Review for Nontuberculous Mycobacterial Infections by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 85: UK 16-Year Perspective for Nontuberculous Mycobacterial Infections by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2014, 2025 & 2030
  • SPAIN
    • TABLE 86: Spain Recent Past, Current & Future Analysis for Nontuberculous Mycobacterial Infections by Drug Type - Clarithromycin, Azithromycin, Rifampin, Rifabutin and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 87: Spain Historic Review for Nontuberculous Mycobacterial Infections by Drug Type - Clarithromycin, Azithromycin, Rifampin, Rifabutin and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 88: Spain 16-Year Perspective for Nontuberculous Mycobacterial Infections by Drug Type - Percentage Breakdown of Value Sales for Clarithromycin, Azithromycin, Rifampin, Rifabutin and Other Drug Types for the Years 2014, 2025 & 2030
    • TABLE 89: Spain Recent Past, Current & Future Analysis for Nontuberculous Mycobacterial Infections by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 90: Spain Historic Review for Nontuberculous Mycobacterial Infections by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 91: Spain 16-Year Perspective for Nontuberculous Mycobacterial Infections by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2014, 2025 & 2030
  • RUSSIA
    • TABLE 92: Russia Recent Past, Current & Future Analysis for Nontuberculous Mycobacterial Infections by Drug Type - Clarithromycin, Azithromycin, Rifampin, Rifabutin and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 93: Russia Historic Review for Nontuberculous Mycobacterial Infections by Drug Type - Clarithromycin, Azithromycin, Rifampin, Rifabutin and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 94: Russia 16-Year Perspective for Nontuberculous Mycobacterial Infections by Drug Type - Percentage Breakdown of Value Sales for Clarithromycin, Azithromycin, Rifampin, Rifabutin and Other Drug Types for the Years 2014, 2025 & 2030
    • TABLE 95: Russia Recent Past, Current & Future Analysis for Nontuberculous Mycobacterial Infections by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 96: Russia Historic Review for Nontuberculous Mycobacterial Infections by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 97: Russia 16-Year Perspective for Nontuberculous Mycobacterial Infections by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2014, 2025 & 2030
  • REST OF EUROPE
    • TABLE 98: Rest of Europe Recent Past, Current & Future Analysis for Nontuberculous Mycobacterial Infections by Drug Type - Clarithromycin, Azithromycin, Rifampin, Rifabutin and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 99: Rest of Europe Historic Review for Nontuberculous Mycobacterial Infections by Drug Type - Clarithromycin, Azithromycin, Rifampin, Rifabutin and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 100: Rest of Europe 16-Year Perspective for Nontuberculous Mycobacterial Infections by Drug Type - Percentage Breakdown of Value Sales for Clarithromycin, Azithromycin, Rifampin, Rifabutin and Other Drug Types for the Years 2014, 2025 & 2030
    • TABLE 101: Rest of Europe Recent Past, Current & Future Analysis for Nontuberculous Mycobacterial Infections by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 102: Rest of Europe Historic Review for Nontuberculous Mycobacterial Infections by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 103: Rest of Europe 16-Year Perspective for Nontuberculous Mycobacterial Infections by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2014, 2025 & 2030
  • ASIA-PACIFIC
    • Nontuberculous Mycobacterial Infections Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 104: Asia-Pacific Recent Past, Current & Future Analysis for Nontuberculous Mycobacterial Infections by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 105: Asia-Pacific Historic Review for Nontuberculous Mycobacterial Infections by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 106: Asia-Pacific 16-Year Perspective for Nontuberculous Mycobacterial Infections by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2014, 2025 & 2030
    • TABLE 107: Asia-Pacific Recent Past, Current & Future Analysis for Nontuberculous Mycobacterial Infections by Drug Type - Clarithromycin, Azithromycin, Rifampin, Rifabutin and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 108: Asia-Pacific Historic Review for Nontuberculous Mycobacterial Infections by Drug Type - Clarithromycin, Azithromycin, Rifampin, Rifabutin and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 109: Asia-Pacific 16-Year Perspective for Nontuberculous Mycobacterial Infections by Drug Type - Percentage Breakdown of Value Sales for Clarithromycin, Azithromycin, Rifampin, Rifabutin and Other Drug Types for the Years 2014, 2025 & 2030
    • TABLE 110: Asia-Pacific Recent Past, Current & Future Analysis for Nontuberculous Mycobacterial Infections by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 111: Asia-Pacific Historic Review for Nontuberculous Mycobacterial Infections by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 112: Asia-Pacific 16-Year Perspective for Nontuberculous Mycobacterial Infections by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2014, 2025 & 2030
  • AUSTRALIA
    • Nontuberculous Mycobacterial Infections Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
    • TABLE 113: Australia Recent Past, Current & Future Analysis for Nontuberculous Mycobacterial Infections by Drug Type - Clarithromycin, Azithromycin, Rifampin, Rifabutin and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 114: Australia Historic Review for Nontuberculous Mycobacterial Infections by Drug Type - Clarithromycin, Azithromycin, Rifampin, Rifabutin and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 115: Australia 16-Year Perspective for Nontuberculous Mycobacterial Infections by Drug Type - Percentage Breakdown of Value Sales for Clarithromycin, Azithromycin, Rifampin, Rifabutin and Other Drug Types for the Years 2014, 2025 & 2030
    • TABLE 116: Australia Recent Past, Current & Future Analysis for Nontuberculous Mycobacterial Infections by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 117: Australia Historic Review for Nontuberculous Mycobacterial Infections by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 118: Australia 16-Year Perspective for Nontuberculous Mycobacterial Infections by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2014, 2025 & 2030
  • INDIA
    • Nontuberculous Mycobacterial Infections Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
    • TABLE 119: India Recent Past, Current & Future Analysis for Nontuberculous Mycobacterial Infections by Drug Type - Clarithromycin, Azithromycin, Rifampin, Rifabutin and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 120: India Historic Review for Nontuberculous Mycobacterial Infections by Drug Type - Clarithromycin, Azithromycin, Rifampin, Rifabutin and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 121: India 16-Year Perspective for Nontuberculous Mycobacterial Infections by Drug Type - Percentage Breakdown of Value Sales for Clarithromycin, Azithromycin, Rifampin, Rifabutin and Other Drug Types for the Years 2014, 2025 & 2030
    • TABLE 122: India Recent Past, Current & Future Analysis for Nontuberculous Mycobacterial Infections by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 123: India Historic Review for Nontuberculous Mycobacterial Infections by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 124: India 16-Year Perspective for Nontuberculous Mycobacterial Infections by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2014, 2025 & 2030
  • SOUTH KOREA
    • TABLE 125: South Korea Recent Past, Current & Future Analysis for Nontuberculous Mycobacterial Infections by Drug Type - Clarithromycin, Azithromycin, Rifampin, Rifabutin and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 126: South Korea Historic Review for Nontuberculous Mycobacterial Infections by Drug Type - Clarithromycin, Azithromycin, Rifampin, Rifabutin and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 127: South Korea 16-Year Perspective for Nontuberculous Mycobacterial Infections by Drug Type - Percentage Breakdown of Value Sales for Clarithromycin, Azithromycin, Rifampin, Rifabutin and Other Drug Types for the Years 2014, 2025 & 2030
    • TABLE 128: South Korea Recent Past, Current & Future Analysis for Nontuberculous Mycobacterial Infections by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 129: South Korea Historic Review for Nontuberculous Mycobacterial Infections by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 130: South Korea 16-Year Perspective for Nontuberculous Mycobacterial Infections by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2014, 2025 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 131: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Nontuberculous Mycobacterial Infections by Drug Type - Clarithromycin, Azithromycin, Rifampin, Rifabutin and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 132: Rest of Asia-Pacific Historic Review for Nontuberculous Mycobacterial Infections by Drug Type - Clarithromycin, Azithromycin, Rifampin, Rifabutin and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 133: Rest of Asia-Pacific 16-Year Perspective for Nontuberculous Mycobacterial Infections by Drug Type - Percentage Breakdown of Value Sales for Clarithromycin, Azithromycin, Rifampin, Rifabutin and Other Drug Types for the Years 2014, 2025 & 2030
    • TABLE 134: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Nontuberculous Mycobacterial Infections by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 135: Rest of Asia-Pacific Historic Review for Nontuberculous Mycobacterial Infections by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 136: Rest of Asia-Pacific 16-Year Perspective for Nontuberculous Mycobacterial Infections by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2014, 2025 & 2030
  • LATIN AMERICA
    • Nontuberculous Mycobacterial Infections Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
    • TABLE 137: Latin America Recent Past, Current & Future Analysis for Nontuberculous Mycobacterial Infections by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 138: Latin America Historic Review for Nontuberculous Mycobacterial Infections by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 139: Latin America 16-Year Perspective for Nontuberculous Mycobacterial Infections by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2014, 2025 & 2030
    • TABLE 140: Latin America Recent Past, Current & Future Analysis for Nontuberculous Mycobacterial Infections by Drug Type - Clarithromycin, Azithromycin, Rifampin, Rifabutin and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 141: Latin America Historic Review for Nontuberculous Mycobacterial Infections by Drug Type - Clarithromycin, Azithromycin, Rifampin, Rifabutin and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 142: Latin America 16-Year Perspective for Nontuberculous Mycobacterial Infections by Drug Type - Percentage Breakdown of Value Sales for Clarithromycin, Azithromycin, Rifampin, Rifabutin and Other Drug Types for the Years 2014, 2025 & 2030
    • TABLE 143: Latin America Recent Past, Current & Future Analysis for Nontuberculous Mycobacterial Infections by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 144: Latin America Historic Review for Nontuberculous Mycobacterial Infections by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 145: Latin America 16-Year Perspective for Nontuberculous Mycobacterial Infections by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2014, 2025 & 2030
  • ARGENTINA
    • TABLE 146: Argentina Recent Past, Current & Future Analysis for Nontuberculous Mycobacterial Infections by Drug Type - Clarithromycin, Azithromycin, Rifampin, Rifabutin and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 147: Argentina Historic Review for Nontuberculous Mycobacterial Infections by Drug Type - Clarithromycin, Azithromycin, Rifampin, Rifabutin and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 148: Argentina 16-Year Perspective for Nontuberculous Mycobacterial Infections by Drug Type - Percentage Breakdown of Value Sales for Clarithromycin, Azithromycin, Rifampin, Rifabutin and Other Drug Types for the Years 2014, 2025 & 2030
    • TABLE 149: Argentina Recent Past, Current & Future Analysis for Nontuberculous Mycobacterial Infections by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 150: Argentina Historic Review for Nontuberculous Mycobacterial Infections by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 151: Argentina 16-Year Perspective for Nontuberculous Mycobacterial Infections by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2014, 2025 & 2030
  • BRAZIL
    • TABLE 152: Brazil Recent Past, Current & Future Analysis for Nontuberculous Mycobacterial Infections by Drug Type - Clarithromycin, Azithromycin, Rifampin, Rifabutin and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 153: Brazil Historic Review for Nontuberculous Mycobacterial Infections by Drug Type - Clarithromycin, Azithromycin, Rifampin, Rifabutin and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 154: Brazil 16-Year Perspective for Nontuberculous Mycobacterial Infections by Drug Type - Percentage Breakdown of Value Sales for Clarithromycin, Azithromycin, Rifampin, Rifabutin and Other Drug Types for the Years 2014, 2025 & 2030
    • TABLE 155: Brazil Recent Past, Current & Future Analysis for Nontuberculous Mycobacterial Infections by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 156: Brazil Historic Review for Nontuberculous Mycobacterial Infections by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 157: Brazil 16-Year Perspective for Nontuberculous Mycobacterial Infections by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2014, 2025 & 2030
  • MEXICO
    • TABLE 158: Mexico Recent Past, Current & Future Analysis for Nontuberculous Mycobacterial Infections by Drug Type - Clarithromycin, Azithromycin, Rifampin, Rifabutin and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 159: Mexico Historic Review for Nontuberculous Mycobacterial Infections by Drug Type - Clarithromycin, Azithromycin, Rifampin, Rifabutin and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 160: Mexico 16-Year Perspective for Nontuberculous Mycobacterial Infections by Drug Type - Percentage Breakdown of Value Sales for Clarithromycin, Azithromycin, Rifampin, Rifabutin and Other Drug Types for the Years 2014, 2025 & 2030
    • TABLE 161: Mexico Recent Past, Current & Future Analysis for Nontuberculous Mycobacterial Infections by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 162: Mexico Historic Review for Nontuberculous Mycobacterial Infections by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 163: Mexico 16-Year Perspective for Nontuberculous Mycobacterial Infections by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2014, 2025 & 2030
  • REST OF LATIN AMERICA
    • TABLE 164: Rest of Latin America Recent Past, Current & Future Analysis for Nontuberculous Mycobacterial Infections by Drug Type - Clarithromycin, Azithromycin, Rifampin, Rifabutin and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 165: Rest of Latin America Historic Review for Nontuberculous Mycobacterial Infections by Drug Type - Clarithromycin, Azithromycin, Rifampin, Rifabutin and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 166: Rest of Latin America 16-Year Perspective for Nontuberculous Mycobacterial Infections by Drug Type - Percentage Breakdown of Value Sales for Clarithromycin, Azithromycin, Rifampin, Rifabutin and Other Drug Types for the Years 2014, 2025 & 2030
    • TABLE 167: Rest of Latin America Recent Past, Current & Future Analysis for Nontuberculous Mycobacterial Infections by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 168: Rest of Latin America Historic Review for Nontuberculous Mycobacterial Infections by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 169: Rest of Latin America 16-Year Perspective for Nontuberculous Mycobacterial Infections by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2014, 2025 & 2030
  • MIDDLE EAST
    • Nontuberculous Mycobacterial Infections Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
    • TABLE 170: Middle East Recent Past, Current & Future Analysis for Nontuberculous Mycobacterial Infections by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 171: Middle East Historic Review for Nontuberculous Mycobacterial Infections by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 172: Middle East 16-Year Perspective for Nontuberculous Mycobacterial Infections by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2014, 2025 & 2030
    • TABLE 173: Middle East Recent Past, Current & Future Analysis for Nontuberculous Mycobacterial Infections by Drug Type - Clarithromycin, Azithromycin, Rifampin, Rifabutin and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 174: Middle East Historic Review for Nontuberculous Mycobacterial Infections by Drug Type - Clarithromycin, Azithromycin, Rifampin, Rifabutin and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 175: Middle East 16-Year Perspective for Nontuberculous Mycobacterial Infections by Drug Type - Percentage Breakdown of Value Sales for Clarithromycin, Azithromycin, Rifampin, Rifabutin and Other Drug Types for the Years 2014, 2025 & 2030
    • TABLE 176: Middle East Recent Past, Current & Future Analysis for Nontuberculous Mycobacterial Infections by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 177: Middle East Historic Review for Nontuberculous Mycobacterial Infections by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 178: Middle East 16-Year Perspective for Nontuberculous Mycobacterial Infections by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2014, 2025 & 2030
  • IRAN
    • TABLE 179: Iran Recent Past, Current & Future Analysis for Nontuberculous Mycobacterial Infections by Drug Type - Clarithromycin, Azithromycin, Rifampin, Rifabutin and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 180: Iran Historic Review for Nontuberculous Mycobacterial Infections by Drug Type - Clarithromycin, Azithromycin, Rifampin, Rifabutin and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 181: Iran 16-Year Perspective for Nontuberculous Mycobacterial Infections by Drug Type - Percentage Breakdown of Value Sales for Clarithromycin, Azithromycin, Rifampin, Rifabutin and Other Drug Types for the Years 2014, 2025 & 2030
    • TABLE 182: Iran Recent Past, Current & Future Analysis for Nontuberculous Mycobacterial Infections by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 183: Iran Historic Review for Nontuberculous Mycobacterial Infections by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 184: Iran 16-Year Perspective for Nontuberculous Mycobacterial Infections by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2014, 2025 & 2030
  • ISRAEL
    • TABLE 185: Israel Recent Past, Current & Future Analysis for Nontuberculous Mycobacterial Infections by Drug Type - Clarithromycin, Azithromycin, Rifampin, Rifabutin and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 186: Israel Historic Review for Nontuberculous Mycobacterial Infections by Drug Type - Clarithromycin, Azithromycin, Rifampin, Rifabutin and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 187: Israel 16-Year Perspective for Nontuberculous Mycobacterial Infections by Drug Type - Percentage Breakdown of Value Sales for Clarithromycin, Azithromycin, Rifampin, Rifabutin and Other Drug Types for the Years 2014, 2025 & 2030
    • TABLE 188: Israel Recent Past, Current & Future Analysis for Nontuberculous Mycobacterial Infections by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 189: Israel Historic Review for Nontuberculous Mycobacterial Infections by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 190: Israel 16-Year Perspective for Nontuberculous Mycobacterial Infections by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2014, 2025 & 2030
  • SAUDI ARABIA
    • TABLE 191: Saudi Arabia Recent Past, Current & Future Analysis for Nontuberculous Mycobacterial Infections by Drug Type - Clarithromycin, Azithromycin, Rifampin, Rifabutin and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 192: Saudi Arabia Historic Review for Nontuberculous Mycobacterial Infections by Drug Type - Clarithromycin, Azithromycin, Rifampin, Rifabutin and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 193: Saudi Arabia 16-Year Perspective for Nontuberculous Mycobacterial Infections by Drug Type - Percentage Breakdown of Value Sales for Clarithromycin, Azithromycin, Rifampin, Rifabutin and Other Drug Types for the Years 2014, 2025 & 2030
    • TABLE 194: Saudi Arabia Recent Past, Current & Future Analysis for Nontuberculous Mycobacterial Infections by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 195: Saudi Arabia Historic Review for Nontuberculous Mycobacterial Infections by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 196: Saudi Arabia 16-Year Perspective for Nontuberculous Mycobacterial Infections by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2014, 2025 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 197: UAE Recent Past, Current & Future Analysis for Nontuberculous Mycobacterial Infections by Drug Type - Clarithromycin, Azithromycin, Rifampin, Rifabutin and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 198: UAE Historic Review for Nontuberculous Mycobacterial Infections by Drug Type - Clarithromycin, Azithromycin, Rifampin, Rifabutin and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 199: UAE 16-Year Perspective for Nontuberculous Mycobacterial Infections by Drug Type - Percentage Breakdown of Value Sales for Clarithromycin, Azithromycin, Rifampin, Rifabutin and Other Drug Types for the Years 2014, 2025 & 2030
    • TABLE 200: UAE Recent Past, Current & Future Analysis for Nontuberculous Mycobacterial Infections by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 201: UAE Historic Review for Nontuberculous Mycobacterial Infections by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 202: UAE 16-Year Perspective for Nontuberculous Mycobacterial Infections by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2014, 2025 & 2030
  • REST OF MIDDLE EAST
    • TABLE 203: Rest of Middle East Recent Past, Current & Future Analysis for Nontuberculous Mycobacterial Infections by Drug Type - Clarithromycin, Azithromycin, Rifampin, Rifabutin and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 204: Rest of Middle East Historic Review for Nontuberculous Mycobacterial Infections by Drug Type - Clarithromycin, Azithromycin, Rifampin, Rifabutin and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 205: Rest of Middle East 16-Year Perspective for Nontuberculous Mycobacterial Infections by Drug Type - Percentage Breakdown of Value Sales for Clarithromycin, Azithromycin, Rifampin, Rifabutin and Other Drug Types for the Years 2014, 2025 & 2030
    • TABLE 206: Rest of Middle East Recent Past, Current & Future Analysis for Nontuberculous Mycobacterial Infections by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 207: Rest of Middle East Historic Review for Nontuberculous Mycobacterial Infections by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 208: Rest of Middle East 16-Year Perspective for Nontuberculous Mycobacterial Infections by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2014, 2025 & 2030
  • AFRICA
    • Nontuberculous Mycobacterial Infections Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
    • TABLE 209: Africa Recent Past, Current & Future Analysis for Nontuberculous Mycobacterial Infections by Drug Type - Clarithromycin, Azithromycin, Rifampin, Rifabutin and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 210: Africa Historic Review for Nontuberculous Mycobacterial Infections by Drug Type - Clarithromycin, Azithromycin, Rifampin, Rifabutin and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 211: Africa 16-Year Perspective for Nontuberculous Mycobacterial Infections by Drug Type - Percentage Breakdown of Value Sales for Clarithromycin, Azithromycin, Rifampin, Rifabutin and Other Drug Types for the Years 2014, 2025 & 2030
    • TABLE 212: Africa Recent Past, Current & Future Analysis for Nontuberculous Mycobacterial Infections by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 213: Africa Historic Review for Nontuberculous Mycobacterial Infections by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 214: Africa 16-Year Perspective for Nontuberculous Mycobacterial Infections by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2014, 2025 & 2030

IV. COMPETITION

Show more
Have a question?
Picture

Jeroen Van Heghe

Manager - EMEA

+32-2-535-7543

Picture

Christine Sirois

Manager - Americas

+1-860-674-8796

Questions? Please give us a call or visit the contact form.
Contact Us +1-866-353-3335
Hi, how can we help?
Contact us!